Phospho-AURKB/AURKC (T236/202) Antibody

What are the structural and functional differences between AURKB and AURKC?

AURKB and AURKC are highly homologous members of the Aurora kinase family with 75% sequence identity in their kinase domains . While structurally similar, they have distinct functions and expression patterns. AURKB catalyzes critical phosphorylation events in mitosis and is broadly expressed across cell types, whereas AURKC is primarily expressed in gametes and plays an important role in meiotic processes . Both kinases require activation through binding to the C-terminal domain of INCENP, followed by phosphorylation of specific residues in their activation loops. The key distinction lies in their regulatory domains - AURKC lacks the N-terminal domain found in AURKB containing the KEN and D-box activating domain (DAD/A-box) motifs, suggesting differential regulation mechanisms .

What is the significance of T236/202 phosphorylation sites in AURKB/AURKC?

The T236 (AURKB) and T202 (AURKC) phosphorylation sites are located within the activation loop (T-loop) of these kinases and are critical for their enzymatic activity . Phosphorylation at these conserved threonine residues induces conformational changes that stabilize the active site and enhance substrate recognition. Crystallographic studies have revealed that phosphorylation of these sites promotes a disorder-to-order transition in the activation loop, creating an optimized substrate-binding surface . This post-translational modification serves as a molecular switch that converts these kinases from inactive to catalytically active forms capable of phosphorylating downstream targets involved in chromosome segregation and cytokinesis.

How do Aurora kinases interact with INCENP to achieve full activation?

The full activation of AURKB and AURKC follows a multi-step process:

• Initial binding: The kinases bind to the C-terminal IN-box region of INCENP (residues 835-903 in humans)

• Auto-phosphorylation: This binding promotes auto-phosphorylation of the kinase at its activation loop threonine (T232 in AURKB, T198 in AURKC)

• INCENP phosphorylation: The partially active kinase then phosphorylates the conserved TSS motif of INCENP at serine residues (S893 and S894)

• Synergistic activation: Phosphorylated INCENP residues form hydrogen bonds with specific residues in the kinase (including Arg196), stabilizing the activation loop in its active conformation

This represents a sophisticated feedback mechanism where the initial kinase activity enhances INCENP phosphorylation, which in turn further activates the kinase in a synergistic manner .

What criteria should researchers consider when selecting between different Phospho-AURKB/AURKC antibodies?

When selecting Phospho-AURKB/AURKC antibodies for research, consider these critical factors:

For maximum experimental flexibility, researchers might consider antibodies validated across multiple applications, such as the Anti-Phospho-ARK-2/3 (T236/202) AURKB Antibody (A00762T236) validated for ELISA and IHC .

What are the optimal methods for using Phospho-AURKB/AURKC antibodies in immunohistochemistry?

For optimal immunohistochemistry (IHC) results with Phospho-AURKB/AURKC antibodies:

• Sample preparation:

  • Use freshly prepared 4% paraformaldehyde-fixed, paraffin-embedded tissues

  • Section tissues at 4-6 μm thickness

  • Include positive control tissues (e.g., human brain samples have shown successful staining with AurB/C phospho-antibodies)

• Antigen retrieval:

  • Perform heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Heat at 95-100°C for 15-20 minutes followed by cooling to room temperature

• Blocking and antibody dilution:

  • Block with 5-10% normal serum from the same species as the secondary antibody

  • Use recommended antibody dilutions (e.g., 1:100-1:300 for IHC with Anti-Phospho-ARK-2/3)

  • Incubate at 4°C overnight for optimal signal-to-noise ratio

• Controls:

  • Include phospho-peptide blocking controls to verify specificity

  • The immunohistochemistry analysis of human brain tissue demonstrated specificity when blocked with phospho-peptide

• Detection and visualization:

  • Use compatible secondary antibody systems (e.g., HRP-polymer detection)

  • Optimize DAB development time (typically 2-10 minutes)

  • Counterstain with hematoxylin for nuclear contrast

This methodology enables precise localization of phosphorylated AURKB/AURKC in tissue contexts, particularly useful for cancer research and developmental studies.

How can researchers validate the specificity of Phospho-AURKB/AURKC antibodies?

Rigorous validation of phospho-specific antibodies is essential for experimental reliability. Implement these complementary approaches:

• Phosphatase treatment controls:

  • Split your sample and treat half with lambda phosphatase

  • A genuine phospho-specific antibody will show reduced or absent signal in the phosphatase-treated sample

• Phospho-peptide competition:

  • Pre-incubate antibody with phosphorylated peptide immunogen

  • This should block specific binding and reduce signal, as demonstrated with AurB/C (Phospho-Thr236/202) antibody

• Kinase inhibitor experiments:

  • Treat cells with Aurora kinase inhibitors (e.g., BRD-7880, a dual AURKB/AURKC-specific inhibitor)

  • This should reduce phosphorylation signals if antibody is specific

• Phospho-mimetic and phospho-dead mutants:

  • Generate T236A/T202A (phospho-dead) and T236D/T202D (phospho-mimetic) mutants

  • Antibody should recognize only wild-type (when phosphorylated) and potentially phospho-mimetic variants

• ELISA cross-reactivity assessment:

  • Test antibody reactivity against phosphorylated versus non-phosphorylated peptides

  • The Phospho-ELISA for Immunogen Phosphopeptide shows clear differentiation between phospho and non-phospho targets

Following these validation strategies ensures that experimental findings accurately reflect the phosphorylation status of AURKB/AURKC in your biological system.

How can researchers distinguish between AURKB and AURKC phosphorylation in gametes where both are expressed?

Distinguishing between AURKB and AURKC phosphorylation in gametes requires a multi-faceted approach:

• Isoform-specific antibody selection:

  • Use antibodies that recognize unique phosphorylation sites or epitopes specific to each isoform

  • Consider that the high sequence homology (75%) in the kinase domain makes absolute specificity challenging

• Genetic approaches:

  • Implement siRNA/shRNA knockdown of either AURKB or AURKC

  • Create CRISPR/Cas9 knockout models for either kinase

  • Analyze remaining phosphorylation patterns with phospho-specific antibodies

• Expression pattern analysis:

  • Leverage the differential expression of AURKC variants in oocytes versus sperm

  • Human oocytes contain all three AURKC variants, while sperm express only one or two variants

• Substrate specificity assessment:

  • Employ known substrates with differential affinity for AURKB versus AURKC

  • Analyze phosphorylation patterns with INCENP mutants that prefer one Aurora kinase isoform over another

• Quantitative phospho-proteomics:

  • Combine immunoprecipitation with mass spectrometry

  • Map phosphorylation sites and quantify relative contributions of each kinase

This integrated approach allows researchers to decipher the distinct roles of these highly similar kinases in complex reproductive cell types where both are functionally relevant.

What role does the phosphorylation of INCENP's TSS motif play in modulating AURKB/AURKC activity?

The phosphorylation of the TSS motif in INCENP represents a sophisticated regulatory mechanism for AURKB/AURKC activity:

• Structural stabilization:

  • Phosphorylated S893 and S894 in INCENP form hydrogen bonds with specific residues in the AURKC activation loop, including Arg196, Thr191, and Ser193

  • This interaction stabilizes the activation loop in its active conformation

• Substrate selectivity modulation:

  • TSS motif phosphorylation significantly affects substrate binding kinetics

  • Enzyme kinetic studies reveal that lack of TSS motif phosphorylation increases Km values for substrates

  • This suggests phosphorylated INCENP alters the substrate selectivity profile of AURKB/AURKC complexes

• Synergistic activation mechanism:

  • The TSS motif phosphorylation works synergistically with Aurora kinase activation loop phosphorylation

  • Crystal structures show that INCENP pS893 and pS894 stabilize AURKC activation loop through a network of hydrogen bonds

• Evolutionary conservation:

  • The residues involved in this interaction are highly conserved through evolution

  • This conservation underscores the fundamental importance of this regulatory mechanism

These findings demonstrate that INCENP phosphorylation is not merely an outcome of Aurora kinase activity but serves as a critical allosteric regulator that fine-tunes kinase function through a feedforward mechanism.

How do AURKB/AURKC phosphorylation patterns change during meiotic versus mitotic cell division?

The phosphorylation patterns of AURKB/AURKC exhibit distinct dynamics between mitotic and meiotic cell divisions:

In meiosis, AURKC (with its three splice variants) appears to have adapted for the unique requirements of reducing chromosome number through two sequential divisions without DNA replication . The variant 1 of AURKC demonstrates enhanced catalytic efficiency for phosphorylating targets in oocytes, suggesting the N-terminus positively regulates its activity specifically in meiotic contexts .

This differential phosphorylation pattern reflects the specialized roles of these kinases in managing the distinct chromosome dynamics required for mitotic versus meiotic cell division.

What are common pitfalls in phospho-AURKB/AURKC antibody experiments and how can they be addressed?

Researchers frequently encounter these challenges when working with phospho-AURKB/AURKC antibodies:

• Poor signal-to-noise ratio:

  • Root cause: Insufficient blocking or suboptimal antibody dilution

  • Solution: Optimize blocking conditions (5-10% normal serum) and follow recommended antibody dilutions (e.g., 1:100-1:300 for IHC, 1:10000 for ELISA)

• False positive signals:

  • Root cause: Cross-reactivity with related kinases or other phosphorylated proteins

  • Solution: Always include phospho-peptide competition controls; validated antibodies show specificity when blocked with phospho-peptide

• Inconsistent phosphorylation detection:

  • Root cause: Rapid dephosphorylation during sample preparation

  • Solution: Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) in all buffers

• Cell cycle-dependent variability:

  • Root cause: Aurora kinase phosphorylation fluctuates throughout the cell cycle

  • Solution: Synchronize cells or sort based on cell cycle stages for consistent results

• Epitope masking:

  • Root cause: Protein-protein interactions hiding the phosphorylation site

  • Solution: Optimize fixation and extraction methods; consider native versus denatured applications

• Antibody storage degradation:

  • Root cause: Repeated freeze-thaw cycles affecting antibody performance

  • Solution: Aliquot antibodies and store at -20°C; for frequent use, store working aliquots at 4°C for up to one month

Implementing these solutions enhances experimental reliability and reproducibility when working with these specialized antibodies.

How can researchers interpret complex phosphorylation patterns of AURKB/AURKC in cancer cells versus normal cells?

Interpreting AURKB/AURKC phosphorylation patterns in cancer versus normal cells requires consideration of multiple factors:

• Quantitative assessment:

  • Measure relative phosphorylation levels using quantitative western blotting or immunofluorescence intensity

  • Compare phospho-to-total protein ratios rather than absolute phosphorylation levels

  • Cancer cells often exhibit hyperphosphorylation of Aurora kinases compared to normal counterparts

• Subcellular localization analysis:

  • Normal cells: Phosphorylated AURKB/AURKC typically localize to centromeres during metaphase and midbody during cytokinesis

  • Cancer cells: May show aberrant localization patterns, including nuclear and cytoplasmic mislocalization

  • Use high-resolution microscopy to map precise subcellular distributions

• Cell cycle correlation:

  • Normal cells: Show tightly regulated phosphorylation restricted to G2/M phases

  • Cancer cells: May exhibit dysregulated timing with phosphorylation occurring in inappropriate cell cycle phases

  • Combine phospho-AURKB/AURKC staining with cell cycle markers (e.g., cyclin B1, pH3S10)

• Substrate phosphorylation profiles:

  • Examine downstream targets (Histone H3S10, CENP-A) to assess functional consequences

  • Cancer cells may show altered substrate preferences or hyperphosphorylation of targets

• Chromosomal passenger complex (CPC) integrity:

  • Evaluate co-localization with other CPC components (INCENP, Survivin, Borealin)

  • Disrupted CPC formation in cancer cells may indicate aberrant regulation

Dysregulation of Aurora kinases is associated with various cancers, making them attractive targets for therapeutic intervention . By systematically analyzing these parameters, researchers can distinguish pathological phosphorylation patterns from normal regulatory events.

What methodological approaches can resolve contradictory results between different phospho-AURKB/AURKC detection techniques?

When faced with contradictory results across detection techniques, implement this systematic resolution approach:

• Orthogonal validation strategy:

  • Employ at least three independent methods (e.g., Western blot, immunofluorescence, ELISA)

  • Compare results with phospho-proteomic mass spectrometry as a reference standard

  • Disagreement between techniques often indicates method-specific artifacts

• Antibody cross-validation:

  • Test multiple antibodies targeting different epitopes of the same phosphorylation site

  • Compare monoclonal and polyclonal antibodies against the same phospho-target

  • Consistent results across different antibodies increase confidence in findings

• Genetic manipulation controls:

  • Use phospho-mimetic (T→D) and phospho-dead (T→A) mutants as controls

  • Apply CRISPR/Cas9 to create endogenous mutations at phosphorylation sites

  • This approach distinguishes genuine phosphorylation signals from artifacts

• Kinase activity measurement:

  • Complement immunodetection with direct kinase activity assays

  • In vitro kinase assays with recombinant proteins can validate cellular observations

  • Correlation between activity and phosphorylation supports true positive results

• Temporal dynamics analysis:

  • Track phosphorylation changes during cell cycle progression

  • Expected patterns (e.g., peaking at metaphase-anaphase transition) support valid detection

  • Unexpected temporal patterns may indicate technical artifacts

• Sample preparation standardization:

  • Implement identical fixation and extraction protocols across techniques

  • Phosphorylation status can change rapidly during sample preparation

  • Use phosphatase inhibitors consistently in all buffers

By systematically addressing these methodological considerations, researchers can resolve contradictions and establish consensus on the true phosphorylation status of AURKB/AURKC in their experimental system.

How might targeting specific phosphorylation sites of AURKB/AURKC inform development of selective therapeutic approaches?

The structural and functional differences in AURKB/AURKC phosphorylation sites present promising opportunities for selective therapeutic targeting:

• Structural-based inhibitor design:

  • Crystal structures of fully activated AURKC:INCENP complexes reveal unique conformational features around T198 phosphorylation

  • These structural insights enable design of inhibitors that exploit subtle differences between AURKB and AURKC active sites

  • BRD-7880, a dual AURKB/AURKC-specific inhibitor, demonstrates the feasibility of targeting these kinases selectively

• Phosphorylation site-specific interventions:

  • Develop compounds that specifically prevent phosphorylation at T236 (AURKB) or T202 (AURKC)

  • Design peptide mimetics that compete with INCENP binding to prevent synergistic activation

  • Target the unique substrate-binding surface created by the phosphorylated activation loop

• Isoform-selective approaches:

  • Leverage the distinct N-terminal domains between AURKB and AURKC for selective targeting

  • AURKC lacks the N-terminal domain containing KEN and D-box motifs found in AURKB

  • This structural difference may allow for selective degradation strategies (e.g., PROTACs)

• Context-dependent therapeutic strategies:

  • Exploit tissue-specific expression patterns (AURKC primarily in gametes) for selective targeting in reproductive contexts

  • Develop conditional systems that only inhibit hyperactivated Aurora kinases typical in cancer cells

  • Design combination approaches targeting both phosphorylation and protein-protein interactions

These targeted approaches may overcome limitations of current pan-Aurora inhibitors, potentially reducing off-target effects while maintaining therapeutic efficacy in appropriate disease contexts.

What emerging technologies will advance our understanding of AURKB/AURKC phosphorylation dynamics?

Several cutting-edge technologies are poised to revolutionize our understanding of AURKB/AURKC phosphorylation dynamics:

• Live-cell phosphorylation biosensors:

  • FRET-based sensors detecting conformational changes upon phosphorylation

  • Genetically encoded biosensors enabling real-time visualization of phosphorylation events

  • These approaches will reveal temporal dynamics previously inaccessible through fixed-cell techniques

• Single-molecule phosphorylation imaging:

  • Super-resolution microscopy (STORM/PALM) combined with phospho-specific probes

  • Single-molecule tracking of individual kinase molecules during cell division

  • Will reveal nanoscale organization and mobility of phosphorylated Aurora kinases

• Quantitative phospho-proteomics:

  • Mass spectrometry-based absolute quantification of phosphorylation stoichiometry

  • Proximity labeling combined with phospho-enrichment to map local phosphorylation environments

  • Will provide systems-level understanding of phosphorylation networks involving AURKB/AURKC

• Cryo-electron tomography:

  • Near-atomic resolution of phosphorylated AURKB/AURKC in native cellular contexts

  • Visualization of structural conformations impossible to capture through crystallography

  • Will bridge the gap between in vitro structural studies and cellular functions

• CRISPR-based phosphorylation reporters:

  • Endogenous tagging of Aurora kinases to monitor phosphorylation without overexpression artifacts

  • Base editing to create phospho-mimetic mutations with minimal cellular disruption

  • Will enable precise manipulation of phosphorylation status in physiologically relevant contexts

These technological advances promise to reveal fundamental insights into how phosphorylation regulates the intricate dance of chromosome segregation orchestrated by Aurora kinases during cell division.